ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,136.99
0.42%
Dow Jones
43,325.80
0.07%
Gold vs US Dollar
2,633.445
0.57%
Brent Oil
72.89
0.00%
Bitcoin
95,670.39
-0.02%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Ascendis Pharma AS (ASND)

  7. Ascendis Pharma AS (ASND) News

Ascendis Pharma AS (ASND)

Ascendis Pharma AS
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:ASND
DateTimeSourceHeadlineSymbolCompany
19/12/202413:30GlobeNewswire Inc.YORVIPATH® (Palopegteriparatide) Now Commercially Available in the United States for the Treatment of Hypoparathyroidism in AdultsNASDAQ:ASNDAscendis Pharma AS
17/12/202411:04Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASNDAscendis Pharma AS
16/12/202413:30GlobeNewswire Inc.New InsiGHTS Trial of TransCon™ hGH (Lonapegsomatropin) in Turner Syndrome Achieved Primary Objective at Week 26NASDAQ:ASNDAscendis Pharma AS
12/12/202421:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASNDAscendis Pharma AS
12/12/202421:01GlobeNewswire Inc.FDA Accepts Ascendis Pharma’s Supplemental Biologics License Application for TransCon™ hGH for the Treatment of Adults with Growth Hormone DeficiencyNASDAQ:ASNDAscendis Pharma AS
11/12/202421:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASNDAscendis Pharma AS
10/12/202422:16Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
10/12/202422:07Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
10/12/202422:02Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
10/12/202421:59Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
10/12/202421:58Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
10/12/202421:55Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
03/12/202421:35Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
19/11/202421:08Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ASNDAscendis Pharma AS
14/11/202421:19Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASNDAscendis Pharma AS
14/11/202421:01GlobeNewswire Inc.Ascendis Pharma Reports Third Quarter 2024 Financial ResultsNASDAQ:ASNDAscendis Pharma AS
14/11/202418:28Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ASNDAscendis Pharma AS
14/11/202414:31Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:ASNDAscendis Pharma AS
13/11/202421:02Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASNDAscendis Pharma AS
07/11/202421:01GlobeNewswire Inc.Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024NASDAQ:ASNDAscendis Pharma AS
04/11/202412:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASNDAscendis Pharma AS
04/11/202412:00GlobeNewswire Inc.Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular DiseasesNASDAQ:ASNDAscendis Pharma AS
09/10/202420:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASNDAscendis Pharma AS
30/09/202412:35Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASNDAscendis Pharma AS
30/09/202412:30GlobeNewswire Inc.Ascendis Pharma Announces Submission of Supplemental Biologics License Application to FDA for TransCon™ hGH for the Treatment of Adults with Growth Hormone DeficiencyNASDAQ:ASNDAscendis Pharma AS
30/09/202412:30GlobeNewswire Inc.New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024NASDAQ:ASNDAscendis Pharma AS
27/09/202420:59Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASNDAscendis Pharma AS
23/09/202420:01Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:ASNDAscendis Pharma AS
20/09/202420:01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ASNDAscendis Pharma AS
20/09/202400:16GlobeNewswire Inc.Ascendis Pharma A/S Announces Pricing of Public Offering of ADSsNASDAQ:ASNDAscendis Pharma AS
 Showing the most relevant articles for your search:NASDAQ:ASND

Your Recent History

LSE
SRSP
Sirius Petroleum
LSE
FIH
Fih
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads